Abstract:Background In the early of 1990’s, several peptides overlapping gp41 CHR region, including SJ-2176, T20, and C34 were reported to have potent HIV-1 fusion inhibitory activity. T20 (generic name: enfuvirtide) was approved by the U.S. FDA as the first HIV-1 fusion inhibitory peptide-based anti-HIV drug. However, its clinical application is limited because of its low potency and low genetic barrier to resistance. Furthermore, its mechanism of action is still elusive. Therefore, it is essential to define T20’s mechanism of action, based on which a new analogous peptide with improved antiviral activity can be designed. Methods The inhibitory activity of peptides on 6HB formation was tested in a temperature-controlled cell-cell fusion assay by flow cytometry using 6HB-specific mAb 2G8; on HIV-1 infection and fusion was assessed by p24 and cell-cell fusion assays. Interaction between different peptides or peptide and antibody was evaluated by ELISA. Results T20 could inhibit 6HB formation at early, but not late, stage of HIV-1 fusion, while T1144 was effective at both stages. T20-SF is much more effective than T20 in binding to FP-P and inhibiting infection of HIV-1, including T20-resistant strains, and FP-P-mediated hemolysis. Conclusion In the early of 1990’s, several peptides overlapping gp41 CHR region, including SJ-2176 (residues 630–659), T20 (residues 638–673), and C34 (residues 628–661) were reported to have potent HIV-1 fusion inhibitory activity. T20 (generic name: enfuvirtide) was approved by the U.S. FDA as the first HIV-1 fusion inhibitory peptide-based anti-HIV drug. However, its clinical application is limited because of its low potency and low genetic barrier to resistance. Furthermore, its mechanism of action is still elusive. Therefore, it is essential to define T20’s mechanism of action, based on which a new analogous peptide with improved antiviral activity against divergent HIV-1 strains, including those resistant to T20. Disclosure No significant relationships.

The Action of TSG101 on HIV-1 Budding and Related Inhibitors

TSG101: A Novel Anti-HIV-1 Drug Target

Tsg101 Exposure on the Surface of Hiv-1 Infected Cells: Implications for Monoclonal Antibody Therapy for Hiv/Aids

Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.

New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle.

Tumor susceptibility gene 101 and Tumorigenesis

ST103 HIV-1 Variants with Mutations in the Gp41 Pocket Region Are Resistant to HIV Fusion Inhibitors with Pocket-Binding Domain, but Sensitive to T20

P848 Revisiting Enfuvirtide’s Mechanism and Designing Its Analog with Improved Activity by Targeting Triple Sites in Gp41

The HIV-1 gag p6: a promising target for therapeutic intervention

Perturbation of TSG101 Protein Affects Cell Cycle Progression.

Identification of a Gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein As a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor

Binding of Peptides Containing D‐Amino Acids to the Tsg101 Tumor Susceptibility Protein

Inhibitors from Natural Products to HIV-1 Reverse Transcriptase, Protease and Integrase

Exploring the druggability of the UEV domain of human TSG101 in search for broad-spectrum antivirals

Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.

A novel sorting strategy of trichosanthin for hijacking human immunodeficiency virus type 1

Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket

High Throughput Screening and Characterization of HIV-1 Entry Inhibitors Targeting Gp41: Theories and Techniques.

[1,2,6-Tri-o-galloyl-beta-d-glucopyranose Inhibits Gp41-Mediated HIV Envelope Fusion with Target Cell Membrane].

Role of TSG101 in Cancer.

2,4,5-Trisubstituted Thiazole Derivatives: A Novel and Potent Class of Non-Nucleoside Inhibitors of Wild Type and Mutant HIV-1 Reverse Transcriptase